U.S. Intravenous Immunoglobulin Market Size, Share & Trends Report

U.S. Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Immunodeficiency Diseases, Multifocal Motor Neuropathy), By Distribution Channel, And Segment Forecasts, 2021 - 2028

  • Report ID: GVR-2-68038-428-4
  • Number of Pages: 100
  • Format: Electronic (PDF)
  • Historical Range: 2016 - 2019
  • Industry: Healthcare

Table of Contents

Chapter 1 Methodology and Scope
                 1.1 Market segmentation & scope
                 1.2 Market definition
                 1.3 Information procurement
                      1.3.1 Purchased database
                      1.3.2 GVR’s internal database
                      1.3.3 Secondary sources & third party perspectives
                      1.3.4 Primary research
                 1.4 Information analysis
                      1.4.1 Data analysis models
                 1.5 Market formulation & data visualization
                 1.6 Data validation & publishing
Chapter 2 Executive Summary
                 2.1 Market Outlook
                 2.2 Segment Outlook
                 2.3 Competitive Insights
Chapter 3 U.S. Intravenous Immunoglobulin (IVIG) Market Variables, Trends & Scope
                 3.1 Market Lineage Outlook
                      3.1.1 Parent Market Outlook
                      3.1.2 Ancillary Market Outlook
                 3.2 Penetration and Growth Prospect Mapping
                 3.3 Market Dynamics
                      3.3.1 Market driver analysis
                            3.3.1.1 Rising number of immunodeficiency disease cases
                            3.3.1.2 Rising adoption of immunoglobulin replacement therapies
                            3.3.1.3 Approval and launch of novel products
                            3.3.1.4 Increasing R&D investments
                      3.3.2 Market restraint analysis
                            3.3.2.1 Cost-intensive nature of immunoglobulin replacement therapy
                            3.3.2.2 Stringent regulations pertaining to production and approval
                      3.3.3 Industry opportunity
                 3.4 U.S. Intravenous Immunoglobulin (IVIG) Market Analysis Tools
                      3.4.1 Industry analysis - Porter’s
                            3.4.1.1 Supplier Power
                            3.4.1.2 Buyer Power
                            3.4.1.3 Substitution Threat
                            3.4.1.4 Threat from new entrants
                            3.4.1.5 Competitive Rivalry
                      3.4.2 PESTEL Analysis
                            3.4.2.1 Political Landscape
                            3.4.2.2 Environmental Landscape
                            3.4.2.3 Social landscape
                            3.4.2.4 Technology landscape
                            3.4.2.5 Legal Landscape
                 3.4 COVID-19 Impact on U.S. Intravenous Immunoglobulin (IVIG) Market
Chapter 4 U.S. Intravenous Immunoglobulin (IVIG) Market - Competitive Analysis
                 4.1 Recent Developments & Impact Analysis, by Key Market Participants
                 4.2 Vendor Landscape
                      4.2.1 List of key distributors and channel partners
                 4.3 Public Companies
                      4.3.1 Company market position analysis
                      4.3.2 Competitive dashboard analysis
                 4.4 Private Companies
                      4.4.1 List of key emerging companies
                      4.4.2 Company market position analysis
Chapter 5 U.S. Intravenous Immunoglobulin (IVIG) Market: Application Estimates And Trend Analysis
                 5.1 Definition & Scope
                 5.2 Application Market Share Analysis, 2020 & 2028
                 5.3 Segment Dashboard
                 5.4 Market, by Application, 2016 to 2028
                 5.5 Market Size & Forecasts and Trend Analyses, 2016 to 2028
                      5.5.1 Hypogammaglobulinemia
                            5.5.1.1 Market Estimates and Forecasts, 2016 to 2028 (USD Million)
                      5.5.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                            5.5.2.1 Market Estimates and Forecasts, 2016 to 2028 (USD Million)
                      5.5.3 Immunodeficiency Diseases
                            5.5.3.1 Market Estimates and Forecasts, 2016 to 2028 (USD Million)
                      5.5.4 Congenital AIDS
                            5.5.4.1 Market Estimates and Forecasts, 2016 to 2028 (USD Million)
                      5.5.5 Chronic Lymphocytic Leukemia
                            5.5.5.1 Market Estimates and Forecasts, 2016 to 2028 (USD Million)
                      5.5.6 Myasthenia Gravis
                            5.5.6.1 Market Estimates and Forecasts, 2016 to 2028 (USD Million)
                      5.5.7 Multifocal Motor Neuropathy
                            5.5.7.1 Market Estimates and Forecasts, 2016 to 2028 (USD Million)
                      5.5.8 ITP
                            5.5.8.1 Market Estimates and Forecasts, 2016 to 2028 (USD Million)
                      5.5.9 Kawasaki Disease
                            5.5.9.1 Market Estimates and Forecasts, 2016 to 2028 (USD Million)
                      5.5.10 Guillain-Barré Syndrome (GBS)
                            5.5.10.1 Market Estimates and Forecasts, 2016 to 2028 (USD Million)
                      5.5.11 Others
                            5.5.11.1 Market Estimates and Forecasts, 2016 to 2028 (USD Million)
Chapter 6 U.S. Intravenous Immunoglobulin (IVIG) Market: Distribution Channel Estimates And Trend Analysis
                 6.1 Definition & Scope
                 6.2 Market Share Analysis, 2020 & 2028
                 6.3 Segment Dashboard
                 6.4 Market, by Distribution Channel, 2016 to 2028
                 6.5 Market Size & Forecasts and Trend Analyses, 2016 to 2028
                      6.5.1 Hospital Pharmacy
                            6.5.1.1 Market Estimates and Forecasts, 2016 to 2028 (USD Million)
                      6.5.2 Specialty Pharmacy
                            6.5.2.1 Market Estimates and Forecasts, 2016 to 2028 (USD Million)
                      6.5.3 Others
                            6.5.3.1 Market Estimates and Forecasts, 2016 to 2028 (USD Million)
Chapter 7 Company Profile
                 7.1 Company Profiles
                      7.1.1 Biotest AG
                            7.1.1.1 Company overview
                            7.1.1.2 Financial Performance
                            7.1.1.3 Product benchmarking
                            7.1.1.4 Strategic initiatives
                      7.1.2 Octapharma AG
                            7.1.2.1 Company overview
                            7.1.2.2 Financial Performance
                            7.1.2.3 Product benchmarking
                            7.1.2.4 Strategic initiatives
                      7.1.3 LFB Biotechnologies
                            7.1.3.1 Company overview
                            7.1.3.2 Financial Performance
                            7.1.3.3 Product benchmarking
                            7.1.3.4 Strategic initiatives
                      7.1.4 China Biologics Products, Holdings, Inc.
                            7.1.4.1 Company overview
                            7.1.4.2 Financial Performance
                            7.1.4.3 Product benchmarking
                            7.1.4.4 Strategic initiatives
                      7.1.5 Grifols, S.A.
                            7.1.5.1 Company overview
                            7.1.5.2 Financial Performance
                            7.1.5.3 Product benchmarking
                            7.1.5.4 Strategic initiatives
                      7.1.6 Kedrion Biopharma, Inc.
                            7.1.6.1 Company overview
                            7.1.6.2 Financial Performance
                            7.1.6.3 Product benchmarking
                            7.1.6.4 Strategic initiatives
                      7.1.7 CSL Behring
                            7.1.7.1 Company overview
                            7.1.7.2 Financial Performance
                            7.1.7.3 Product benchmarking
                            7.1.7.4 Strategic initiatives
                      7.1.8 McKesson Corporation
                            7.1.8.1 Company overview
                            7.1.8.2 Financial Performance
                            7.1.8.3 Product benchmarking
                            7.1.8.4 Strategic initiatives
                      7.1.9 Takeda Pharmaceutical Company (Shire plc)
                            7.1.9.1 Company overview
                            7.1.9.2 Financial Performance
                            7.1.9.3 Product benchmarking
                            7.1.9.4 Strategic initiatives
                      7.1.10 Bio Products Laboratory Ltd
                            7.1.10.1 Company overview
                            7.1.10.2 Financial Performance
                            7.1.10.3 Product benchmarking
                            7.1.10.4 Strategic initiatives
                      7.1.11 ADMA Biologics, Inc.
                            7.1.11.1 Company overview
                            7.1.11.2 Financial Performance
                            7.1.11.3 Product benchmarking
                            7.1.11.4 Strategic initiatives
                      7.1.12 Pfizer Inc.
                            7.1.12.1 Company overview
                            7.1.12.2 Financial Performance
                            7.1.12.3 Product benchmarking
                            7.1.12.4 Strategic initiatives


List of Tables

Table 1 List of key distributors and channel partners
Table 2 List of key emerging companies’/technology disruptors/innovators
Table 3 Primary interview details, by source
Table 4 List of secondary data sources
Table 5 List of abbreviation
Table 6 U.S. intravenous immunoglobulin (IVIG) market, by application, 2016 - 2028 (USD Million)
Table 7 U.S. intravenous immunoglobulin (IVIG) market, by distribution channel, 2016 - 2028 (USD Million) 


List of Figures

Fig. 1 U.S. intravenous immunoglobulin (IVIG) market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 U.S. intravenous immunoglobulin (IVIG) market snapshot (2020)
Fig. 9 U.S. intravenous immunoglobulin (IVIG) market: Segment snapshot (2020)
Fig. 10 Competitive Insights (2020)
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 U.S. intravenous immunoglobulin (IVIG) market driver impact
Fig. 15 U.S. intravenous immunoglobulin (IVIG) market restraint impact
Fig. 16 U.S. intravenous immunoglobulin (IVIG) market industry challenges
Fig. 17 Porter’s Five Forces Analysis
Fig. 18 SWOT Analysis, By Factor (Political & legal Economic and technological)
Fig. 19 Strategic alliance analysis
Fig. 20 Recent developments & impact analysis, by key market participants
Fig. 21 Company market position analysis
Fig. 22 Definition and scope, by application
Fig. 23 Application market share analysis, 2020 & 2028
Fig. 24 Segment dashboard
Fig. 25 U.S. intravenous immunoglobulin (IVIG) market, by application, 2016 - 2028 (USD Million)
Fig. 26 Hypogammaglobulinemia market size & forecasts and trend analysis, 2016 to 2028 (USD Million)
Fig. 27 CIDP market size & forecasts and trend analysis, 2016 to 2028 (USD Million)
Fig. 28 Immunodeficiency Diseases market size & forecasts and trend analysis, 2016 to 2028 (USD Million)
Fig. 29 Congenital AIDS market size & forecasts and trend analysis, 2016 to 2028 (USD Million)
Fig. 30 Chronic Lymphocytic Leukemia market size & forecasts and trend analysis, 2016 to 2028 (USD Million)
Fig. 31 Myasthenia Gravis market size & forecasts and trend analysis, 2016 to 2028 (USD Million)
Fig. 32 Multifocal Motor Neuropathy market size & forecasts and trend analysis, 2016 to 2028 (USD Million)
Fig. 33 ITP market size & forecasts and trend analysis, 2016 to 2028 (USD Million)
Fig. 34 Kawasaki Disease market size & forecasts and trend analysis, 2016 to 2028 (USD Million)
Fig. 35 Guillain-barre Syndrome market size & forecasts and trend analysis, 2016 to 2028 (USD Million)
Fig. 36 Others market size & forecasts and trend analysis, 2016 to 2028 (USD Million)
Fig. 37 Definition and scope, by distribution channel
Fig. 38 Distribution channel market share analysis, 2020 & 2028
Fig. 39 Segment dashboard
Fig. 40 U.S. intravenous immunoglobulin (IVIG) market, by distribution channel, 2016 - 2028 (USD Million)
Fig. 41 Hospital pharmacy market size & forecasts and trend analysis, 2016 to 2028 (USD Million)
Fig. 42 Specialty pharmacy market size & forecasts and trend analysis, 2016 to 2028 (USD Million)
Fig. 43 Others market size & forecasts and trend analysis, 2016 to 2028 (USD Million)

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon gvr sidebar D&B icon gvr sidebar

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.